ClinicalTrials.gg
RecruitingNCT05439005OFOBAUpdated Jan 30, 2026

Opioid Free Versus Opioid Based Anaesthesia for Free Flap Reconstruction Surgery of the Breast: A Phase III Multicentric Randomized Controlled Study.

A Phase 3 interventional study of Dexmedetomidine in Breast Cancer, sponsored by Institut Curie. Recruiting at 3 sites in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-30.

Sponsored by Institut Curie · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2022; still recruiting 3 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
158
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies testing dexmedetomidine in Breast Neoplasms — 3 open to participants now, 3 under way, 1 of them phase 3. Dexmedetomidine · Breast Neoplasms.

Planned enrollment
3rd of 14
158 · median 94
Started
2022
the only one that year
Phase 3
3 of 14
1 open now
Registered
9th of 14
by date
Lead sponsor
1 of 14
Institut Curie

Among the 14 studies testing dexmedetomidine in Breast Neoplasms, this one is the 3rd largest by planned enrollment, is the only one that started in 2022, is one of 3 in phase 3, and was the 9th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

3 of the 14 studies testing dexmedetomidine in Breast Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About dexmedetomidine

Dexmedetomidine: first FDA approval 1999 (PRECEDEX), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing dexmedetomidine in Breast Neoplasms, or all of them as a file.
02

Study summary

This study will compare morphine consumption during the first 48 hours postoperatively between the OFA group and the CA control group.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • free flap reconstruction surgery
  • anaesthesia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Women aged 18 or older.
  2. Patients with a French health insurance coverage (having a French social security number).
  3. Patient eligible for free flap reconstruction surgery of the breastunder general anaesthesia.
  4. Patient who has given written consent to participate in accordance with the regulations.
  5. Having a negative blood pregnancy test for patients of childbea ring age.

Exclusion criteria

Exclusion Criteria:

  1. Allergy or intolerance to any of the drugs (dexmedetomidine, remifentanil, lidocaine, propofol, dexamethasone, kétamine, ketoprofen, nefopam, paracetamol, morphine, ropivacaine, droperidol, ondansetron).
  2. Known history of heart failure, arrhythmias and/or ischemic heart disease and/or severe renal insufficiency.
  3. Pulse below 50bpm during anaesthesia consultation and/or under beta blocker treatment.
  4. Treatment with ACEI/ARB.
  5. Severe asthma.
  6. Symptomatic gastric or duodenal ulcer with or without treatment.
  7. Baseline systolic blood pressure \< 100 mmHg.
  8. Chronic preoperative pain and/or use of WHO ladder step 2 or 3 analgesics preoperatively.
  9. Patient already included in another therapeutic trial evaluating an experimental molecule.
  10. Persons deprived of liberty or under guardianship.
  11. Patients with suspected difficulties in assessing pain on a scale.
  12. Inability to undergo trial medical monitoring due to geographic, social or psychological reasons.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
158 participants (estimated)

Study arms

  • Experimental
    OFA group

    OFA (Opioid Free Anaesthesia) group:

    Drug: Dexmedetomidine

  • No intervention
    CA control group

    CA (Conventional Anaesthesia) control group:

Interventions

06

What researchers measure

Primary outcomes

  1. comparison of Morphine consumption in the two groups

    Time frame: during the first 48 hours postoperatively

Secondary outcomes

  1. Assessment of vasopressor requirement and total intraoperative filling volume

    Time frame: end of surgery

  2. Assessment of the state of consciousness on arrival in the PACU

    Time frame: on arrival in the PACU

  3. Assessment of the incidence of PONV in the PACU, at D0, D1 and D2

    Time frame: in the PACU, at D0, D1 and D2

  4. Maximum VAS at rest and mobilization in the PACU, at D0, D1 and D2

    Time frame: in the PACU, at D0, D1 and D2

  5. Dose of morphine given in titration in the PACU (mg)

    Time frame: in the PACU

  6. Number of boluses demand on PCA during the first 48 hours postoperatively

    Time frame: the first 48 hours postoperatively

  7. DN3 score (Neuropathic Pain 3) on D2, D4, M1, M3 and M6

    Time frame: on D2, D4, M1, M3 and M6

  8. Length of stay in PACU (h) and length of in-hospital postoperative length of stay (D)

    Time frame: at discharge

  9. Assessment of the flap failure rate (flap removal surgery) and flap micro-anastomosis re-exploration rate

    Time frame: at discharge

  10. Pain management satisfaction scores (score from 0 to 10) at discharge

    Time frame: at discharge

  11. Collection of serious adverse events between D0 (date of surgery) and D30

    Time frame: between D0 (date of surgery) and D30

  12. Dose of intraoperative rescue remifentanil in the OFA group (mcg)

    Time frame: at discharge

  13. Morphine consumption during the first 48 hours post-operatively (mg) in each breast reconstruction subgroup (immediate and secondary);

    Time frame: the first 48 hours postoperatively

07

Study locations

3 of 3 sites recruiting
08

References and documents

Publications

  • Saad-Boutry M, Carton M, Ezzili C, Savignoni A. Opioid-free versus opioid-based anaesthesia for free-flap reconstruction surgery of the breast: protocol for a phase III, multicentre, randomised controlled study. BMJ Open. 2025 Feb 17;15(2):e070021. doi: 10.1136/bmjopen-2022-070021. PubMed 39961716 ↗

Individual participant data

Plan to share: Yes — Investigators will share de-identified data sets with interested researchers, educators or clinicians. Materials generated under the project will be disseminated in accordance with Institut Curie policies.

Time frame: Data requests can be submitted starting 9 months after article publication and will be made accessible for up to 12 months.

Access criteria: Access to trial individual participant data can be requested by qualified researchers engaging in independent scientific reserach, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a data sharing agreement (DSA).

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2022 (actual). Primary completion is estimated for Jun 2027, 53 months after the start.

Of 328 non-industry phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 79 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 127. This study's planned 53 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2022
First posted
Jun 30, 2022
StartActual
Dec 7, 2022
Primary completionEst.
Jun 6, 2027
CompletionEst.
Jun 6, 2027
Last update
Jan 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05439005
Lead sponsor
Institut Curie
Responsible party
Sponsor
First posted
Jun 30, 2022
Start date
Dec 7, 2022
Primary completion
Jun 6, 2027 (estimated)
Completion
Jun 6, 2027 (estimated)
Last update
Jan 30, 2026

Study contacts

Anne-Claire COYNE, PhD
Contact
anne-claire.coyne@curie.fr
0033156245765
Mary SAAD, MD
Contact
mary.saad@curie.fr
0033147112371
Mary SAAD, MD
study director · Institut Curie Saint-Cloud

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexmedetomidine

Start the discussion